New trials in resistant hypertension: mixed blessing stories

Article Medicine, General & Internal

Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension

Mason W. W. Freeman et al.

Summary: Baxdrostat, a new drug that selectively inhibits aldosterone synthase, has been shown to effectively reduce blood pressure in patients with treatment-resistant hypertension.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

When blood pressure refuses to budge: exploring the complexity of resistant hypertension

Meeti Keyur Champaneria et al.

Summary: Resistant hypertension, which affects a significant proportion of hypertensive population, is characterized by blood pressure remaining above goal despite using multiple antihypertensive medications. Achieving optimal blood pressure control in patients with resistant hypertension remains challenging, but recent advances in the field have identified potential treatment options such as spironolactone, mineralocorticoid receptor antagonists, and renal denervation. Personalized management approaches based on genetic and biomarkers may also offer new opportunities for tailored therapy and improved outcomes.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Akshay S. Desai et al.

Summary: Zilebesiran, an investigational RNA interference therapeutic agent, showed dose-dependent decreases in serum angiotensinogen levels and sustained blood pressure-lowering effect for up to 24 weeks in patients with hypertension. High-salt diet attenuated the blood pressure-lowering effect, while coadministration with irbesartan augmented the effect. Mild injection-site reactions were observed in a few patients throughout the study.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich et al.

Summary: This study evaluated the blood pressure lowering efficacy of the dual endothelin antagonist aprocitentan in patients with resistant hypertension. The results showed that aprocitentan had a blood pressure lowering effect at week 4 and maintained a sustained effect at week 40. The most common adverse event was mild-to-moderate edema or fluid retention.

LANCET (2022)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Chlorthalidone for Resistant Hypertension in Advanced Chronic Kidney Disease

Rajiv Agarwal et al.

CIRCULATION (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta-Analysis Involving 27 Million Patients

Eric K. P. Lee et al.

Summary: Nonadherence to antihypertensive medications is a global problem, especially in low-to middle-income and non-Western countries. Interventions are urgently needed, particularly in these regions.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

添加到收藏夹

Review Peripheral Vascular Disease

Device-Based Therapy for Resistant Hypertension: An Up-to-Date Review

Oussama Jami et al.

Summary: Hypertension is a major risk factor for cardiovascular diseases. Pharmacotherapy can help lower the risk of high blood pressure, but resistant hypertension remains a challenge. Non-pharmacological treatments and device-based therapy have emerged as promising options, supported by studies and clinical trials. However, further research and randomized controlled trials are needed to evaluate the effectiveness of these approaches.

HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2022)

添加到收藏夹

Article Peripheral Vascular Disease

Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study

George Bakris et al.

Summary: In patients with resistant or poorly controlled hypertension and advanced chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist KBP-5074 effectively lowers blood pressure with some risk of hyperkalemia.

HYPERTENSION (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems